Isopentenyl flavone compound as well as preparation method and application thereof

The isoprene flavonoid compounds isolated and prepared from the root and stem skin of Huangrevan, the problem of insufficient effect of existing anti-tumor drugs in liver cancer cell inhibition is solved, and a stronger tumor cell inhibition effect is achieved. It also enriched Huang Ruixiang's chemical research and provided a foundation for structural transformation.

CN118978504AActive Publication Date: 2024-11-19SHENYANG PHARMA UNIV

Patent Information

Application Number
CN202411059144.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

The existing anti-tumor drugs have limited effects in the treatment of tumors such as liver cancer, especially the inhibitory effect on tumor cells is not significant enough. Moreover, the research on the compound structure of traditional Chinese medicine master Ma is relatively single, lacking diversity and depth.

Method used

Three new isoprenyl flavonoid compounds (broussoflavonol C, daphnegiranol G, daphnegiranol E) were separated from the root and stem skin of Huangrevein and prepared. They were extracted by ethanol, ethyl acetate extraction, silica gel column chromatography, HP- 20 macroporous resin, ODS column chromatography and HPLC were isolated and purified, and applied to anti-tumor drugs, especially the inhibitory effect of liver cancer cells.

Benefits of technology

The obtained isoprenylflavonoid compounds show better inhibitory effects in inhibiting tumor cell growth, and have stronger anti-tumor effects than the positive drug Sorafinil, and are chemical and pharmacological research by Huang Ruixiang. It provides a new direction and foundation, laying the foundation for subsequent structural transformation work.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978504A_ABST
    Figure CN118978504A_ABST
Patent Text Reader

Abstract

The invention relates to an isopentenyl flavonoid compound as well as a preparation method and application thereof, belongs to the technical field of medicines, and in particular relates to three isopentenyl flavonoid compounds, namely, broussonol C, daphneol G and daphneol E, which are separated from daphne giraldii Nitch of a daphneaceae daphne plant through chromatographic methods such as silica gel column chromatography, macroporous resin, ODS column chromatography and HPLC (High Performance Liquid Chromatography). The invention also tests the inhibitory activity of the three compounds on Hep3B cells. Finally, it is found that the compound exerts anti-tumor activity by inhibiting the growth activity of tumor cells. The preparation method is simple, the reproducibility is good, the purity of the obtained compound is high, and part of the compound has obvious anti-tumor activity. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine, and specifically relates to three new isopentenyl flavonoid compounds separated from the root bark and stem bark of Daphne koreana and a preparation method thereof and an application thereof in anti-tumor. Background Art

[0002] Daphne giraldii Nitsche is a plant of the genus Daphne in the family Thymelaeaceae. Its root bark and stem bark are used as medicine, and together with the root bark and stem bark of Daphne tangutica and Daphne retusa, they are called Zushima. It is mainly distributed in Shaanxi, Gansu, Qinghai, Sichuan, Xinjiang and other provinces. It is warm in nature, pungent and bitter in taste, slightly toxic, and has the effects of dispelling wind and dampness, relieving pain and dispersing blood stasis. Modern pharmacological studies have shown that Daphne giraldii Nitsche has multiple pharmacological activities such as anti-inflammatory and analgesic, anti-tumor, immunomodulatory, antioxidant, antibacterial, and neuroprotective. The root bark and stem bark of Daphne giraldii Nitsche are rich in chemical components, including coumarins, flavonoids, diterpenes, etc. Among them, isopentenyl flavonoid compounds have good anti-tumor activity.

[0003] Prenylated flavonoids are alkylated products of flavonoid compounds. They are mainly distributed in plants of the Leguminosae and Moraceae families. They are only isolated from Daphne odora in the Thymelaeaceae family. They are characterized by one or more prenylated side chains connected to the parent nucleus of flavonoids through CC or CO bonds, which significantly increase the lipophilicity of flavonoid compounds to improve their biological activity and bioavailability. Due to the high activity of the ortho position of the hydroxyl group on the benzene ring, most of the prenylated groups are substituted at the C-6 and C-8 positions of the A ring and the C-3' and C-5' positions of the B ring. In the process of natural plant synthesis, it often undergoes cyclization, oxidation, dehydration and other reactions with its ortho position phenolic hydroxyl group to form six-membered pyran ring type or five-membered furan ring type prenylated flavonoids. Summary of the invention

[0004] The present invention aims to provide a series of isopentenyl flavonoid compounds separated from the root bark and stem bark of Daphne koreana and a preparation method thereof, as well as application of the compounds in antitumor drugs.

[0005] The structure of the isopentenyl flavonoid compound of the present invention is as follows:

[0006]

[0007] The method for preparing the isopentenyl flavonoid compound of the present invention comprises the following steps:

[0008] The dried root bark and stem bark of Daphne koreana were extracted with ethanol, the extract was concentrated under reduced pressure, the extracts were combined and concentrated to obtain an extract, the extract was extracted with ethyl acetate and n-butanol in sequence, the ethyl acetate extract was then subjected to silica gel column chromatography, HP-20 macroporous resin, ODS, HPLC and other chromatographic methods to finally separate the above three new compounds.

[0009] The specific operations are as follows:

[0010] (1) The dried root bark and stem bark of Daphne koreana were extracted with ethanol, and the combined extracts were concentrated to obtain an extract. The obtained extract was extracted with ethyl acetate and n-butanol successively. The ethyl acetate fraction was subjected to silica gel column chromatography to collect a total of 4 fractions Fr.A-Fr.D;

[0011] (2) Fraction Fr.A was subjected to HP-20 and ODS column chromatography with an ethanol-water gradient elution, and a total of 7 fractions Fr.A1–Fr.A7 were collected;

[0012] (3) The fraction Fr.A5 obtained after elution was subjected to semi-preparative HPLC and further purified by acetonitrile-water system to obtain the isopentenyl flavonoid compound.

[0013] As an optional method, wherein:

[0014] In step (1), the gradient of dichloromethane-methanol is: 100:1-1:1; the ethanol is industrial ethanol with a concentration of 70%, and reflux extraction is performed 3 times, each time for 2 hours.

[0015] In step (2), the gradient of ethanol-water is: 20%-90%.

[0016] In step (3), the acetonitrile-water ratios used for the three compounds are: broussoflavonol C (38:62, v / v), daphnegiranol G (25:75, v / v), and daphnegiranol E (27:78, v / v).

[0017] The structural analysis of the new isopentenyl flavonoid compounds (broussoflavonol C, daphnegiranol G, daphnegiranol E) prepared by the present invention is shown below.

[0018] Compound 1: Yellow amorphous powder (methanol). HRESIMS gives quasi-molecular ion peak [M+H] + m / z437.1972 (calcd for C 26 H 29 O6,437.1959), combined 1 H-NMR, 13The C-NMR spectrum can confirm that the molecular formula of the compound is C 26 H 29 O6, calculated unsaturation is 13, and 1 H-NMR, 13 The C-NMR signal was assigned, and the planar structure was determined by HMBC spectrum. Finally, the compound was determined to be an isopentenyl flavonoid structure. The compound was found to be a new compound that had not been reported before through Scifinder search, and it was named broussoflavonol C. 1 H NMR spectrum, 13 C NMR spectrum signal assignments are shown in Table 1 and related spectra are shown in Figure 1-Figure 6 .

[0019] Table 1 Broussoflavonol C 1 H NMR spectrum and 13 C NMR spectral data

[0020]

[0021]

[0022] Compound 2: red amorphous powder (methanol); HRESIMS gives quasi-molecular ion peak [M+Na] + m / z415.1880(calcd for C 25 H 28 O4Na,415.1878), combined 1 H-NMR, 13 The C-NMR spectrum can confirm that the molecular formula of the compound is C 25 H 28 O4, the calculated unsaturation is 12, and 1 H-NMR, 13 The C-NMR signal was assigned, and the planar structure was determined by HMBC spectrum. Finally, the planar structure of the compound was determined to be an isopentenyl flavonoid structure. The compound was found to be a new compound that had not been reported before through Scifinder search, and it was named daphnegiranol G. 1 H NMR spectrum, 13 C NMR spectrum signal assignments are shown in Table 2, and related spectra are shown in Figure 7-Figure 12 .

[0023] Table 2 Daphnegiranol G 1 H NMR spectrum and 13 C NMR spectral data

[0024]

[0025] Compound 3: red amorphous powder (methanol); HRESIMS gives quasi-molecular ion peak [M+Na] + m / z399.1917 (calcd for C 25 H 28 O3Na,399.1931), combined 1 H-NMR, 13 C-NMR and HSQC NMR can confirm that the molecular formula of the compound is C 25 H 28 O3, the calculated unsaturation is 12, and 1 H-NMR, 13 The C-NMR signal was assigned, and the planar structure was determined by HMBC spectrum. Finally, the planar structure of the compound was determined to be an isopentenyl flavonoid structure. The compound was found to be a new compound that had not been reported before through Scifinder search, and it was named daphnegiranol E. 1 H NMR spectrum, 13 C NMR spectrum signal assignments are shown in Table 3, and related spectra are shown in Figure 13-Figure 18 .

[0026] Table 3 Daphnegiranol E 1 H NMR spectrum and 13 C NMR spectral data

[0027]

[0028] A pharmaceutical composition comprises the isopentenyl flavonoid compound and a pharmaceutically acceptable carrier or excipient.

[0029] Application of the isopentenyl flavonoid compound or the pharmaceutical composition of the present invention in the preparation of anti-tumor drugs.

[0030] Preferably low, the tumor is liver cancer.

[0031] The isopentenyl flavonoid compound of the present invention achieves the purpose of anti-tumor by inhibiting the growth of tumor cells.

[0032] Beneficial effects of the present invention:

[0033] The compound involved in the present invention has a better inhibitory effect on tumor cells than the positive drug sorafenib, and can be prepared from the traditional Chinese medicine Zushima. The present invention enriches the chemical research of Daphne daphne, improves the pharmacological research of Daphne daphne, and provides a research basis for subsequent structural modification work on activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 UV spectrum of compound broussoflavonol C;

[0035] Figure 2 HRESIMS spectrum of compound broussoflavonol C;

[0036] Figure 3 Compound broussoflavonol C 1 H NMR spectrum (DMSO-d6, 600 MHz);

[0037] Figure 4 Compound broussoflavonol C 13 C NMR spectrum (DMSO-d6, 150 MHz);

[0038] Figure 5 HSQC spectrum of compound broussoflavonol C (DMSO-d6, 600MHz);

[0039] Figure 6 HMBC spectrum of compound broussoflavonol C (DMSO-d6, 600MHz);

[0040] Figure 7 UV spectrum of the compound daphnegiranol G;

[0041] Figure 8 HRESIMS spectrum of compound daphnegiranol G;

[0042] Fig. 9 Compound daphnegiranol G 1 H NMR spectrum (DMSO-d6, 600 MHz);

[0043] Fig.10 Compound daphnegiranol G 13 C NMR spectrum (DMSO-d6, 150 MHz);

[0044] Fig.11 HSQC spectrum of compound daphnegiranol G (DMSO-d6, 600MHz);

[0045] Fig.12 HMBC spectrum of compound daphnegiranol G (DMSO-d6, 600MHz);

[0046] Fig.13 UV spectrum of compound daphnegiranol E;

[0047] Fig.14 HRESIMS spectrum of compound daphnegiranol E;

[0048] Fig.15 Compound daphnegiranol E 1 H NMR spectrum (DMSO-d6, 600 MHz);

[0049] Fig.16 Compound daphnegiranol E 13 C NMR spectrum (DMSO-d6, 150 MHz);

[0050] Fig.17 HSQC spectrum of compound daphnegiranol E (DMSO-d6, 600MHz);

[0051] Fig.18 HMBC spectrum of compound daphnegiranol E (DMSO-d6, 600 MHz). DETAILED DESCRIPTION

[0052] Example 1

[0053] Preparation method of isopentenyl flavonoids 1-3:

[0054] (1) Take the dried root bark and stem bark of Daphne koreana (100 kg), grind them into pieces, and extract them with 70% industrial ethanol under heating and reflux for 3 times, each time for 3 hours. Filter the crude extract and concentrate it under reduced pressure to obtain an extract. Add water to the obtained extract, and extract it with ethyl acetate and n-butanol in turn. The ethyl acetate layer (1200 g) is separated by silica gel column chromatography (200-300 mesh), and gradient eluted with dichloromethane-methanol (100:1-1:1) to obtain fractions Fr.A-Fr.D.

[0055] (2) Fraction Fr.A was gradient eluted with ethanol-water (20%-90%) on HP-20 macroporous resin, and then subjected to ODS column chromatography using the same ethanol-water gradient elution. After analysis, seven fractions Fr.A1-Fr.A7 were obtained.

[0056] (4) The fraction Fr.A5 obtained after elution was further purified by semi-preparative HPLC using an acetonitrile-water system to obtain the isopentenyl flavonoid compounds broussoflavonol C (48.6 mg), daphnegiranol G (33.9 mg), and daphnegiranol E (30.4 mg). The acetonitrile-water ratios used for the three compounds were: broussoflavonol C (38:62, v / v), daphnegiranol G (25:75, v / v), and daphnegiranol E (27:78, v / v), respectively.

[0057] Experimental Example 2

[0058] The inhibitory effects of the compounds broussoflavonol C, daphnegiranol G, and daphnegiranol E on Hep3B cells were determined in vitro to explore their anti-tumor activity.

[0059] (1) Cell culture

[0060] Human hepatoma cell Hep3B (purchased from the cell bank of the Chinese Academy of Sciences) were placed in DMEM medium containing 10% fetal bovine serum and 1% double antibody and cultured in an incubator at 37°C and 5% CO2. Cells that were stably subcultured to logarithmic growth were used for experiments.

[0061] (2) Cell grouping

[0062] Blank group: Hep3B cells in the logarithmic growth phase were digested with trypsin and seeded in a 96-well plate at a density of 4000 cells / well. After culturing for 12 hours, 100 μL of blank culture medium was added to each well and cultured for 48 hours. Then, 50 μL of 30% TCA fixative was added to each well and fixed at 4°C for 1 hour.

[0063] Compound 1 group: Hep3B cells in the logarithmic growth phase were digested with trypsin and seeded at a density of 4000 cells / well in a 96-well plate. After culturing for 12 hours, 100 μL of compound broussoflavonol C was added to each well and cultured for 48 hours. Then, 50 μL of 30% TCA fixative was added to each well and fixed at 4°C for 1 hour.

[0064] Compound 2 group: Hep3B cells in the logarithmic growth phase were digested with trypsin and seeded at a density of 4000 cells / well in a 96-well plate. After culturing for 12 hours, 100 μL of compound daphnegiranol G was added to each well and cultured for 48 hours. Then, 50 μL of 30% TCA fixative was added to each well and fixed at 4°C for 1 hour.

[0065] Compound 3 group: Hep3B cells in the logarithmic growth phase were digested with trypsin and seeded at a density of 4000 cells / well in a 96-well plate. After culturing for 12 hours, 100 μL of compound daphnegiranol E was added to each well and cultured for 48 hours. Then, 50 μL of 30% TCA fixative was added to each well and fixed at 4°C for 1 hour.

[0066] Positive drug group: Hep3B cells in the logarithmic growth phase were digested with trypsin and seeded at a density of 4000 cells / well in a 96-well plate. After culturing for 12 h, 100 μL of the positive drug sorafenib (Sora) was added to each well and cultured for 48 hours. Then, 50 μL of 30% TCA fixative was added to each well and fixed at 4°C for 1 hour.

[0067] Shake off the liquid in the wells and rinse with tap water. After drying, add 0.4% SRB (50-70 μL) and stain at room temperature in the dark for 30 minutes. After 30 minutes, dry and rinse the 96-well plate with 1% acetic acid until the liquid is colorless. After drying, add 100 μL of Tris, shake for 20 minutes, and detect with an ELISA reader at a wavelength of 540 nm.

[0068] Growth inhibition rate (%) = [A 540 (Negative control)-A 540 (Drug-adding group)] / A 540 (negative control) × 100%, and then the half-maximal inhibitory concentration (IC 50 ).

[0069] (3) Experimental results

[0070] The tumor cell inhibition data of compounds 1-3 (IC 50 ) as shown in Table 4 below, in μM:

[0071] Table 4: Results of the inhibitory effect of the compounds of the present invention on tumor cells

[0072]

[0073] The experimental results showed that daphnegiranol E had the best inhibitory activity against Hep3B cells, IC 50 The value was 2.53±0.49μM.

[0074] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. An isopentenyl flavonoid compound, characterized in that: It is any one of the compounds shown below; 2. The prenylated flavonoid compound according to claim 1, characterized in that: The isopentenyl flavonoid compound is extracted and separated from the dried root bark and stem bark of Daphne koreana.

3. A method for preparing the isopentenyl flavonoid compound according to claim 1 or claim 2, characterized in that: The following steps are involved: (1) The dried root bark and stem bark of Daphne koreana were extracted with ethanol, and the combined extracts were concentrated to obtain an extract. The obtained extract was extracted with ethyl acetate and n-butanol in turn. The ethyl acetate fraction was subjected to silica gel column chromatography to collect a total of 4 fractions Fr.A-Fr.D; (2) Fraction Fr.A was subjected to HP-20 column chromatography and then to ODS column chromatography with ethanol-water gradient elution, and a total of 7 fractions Fr.A1–Fr.A7 were collected; (3) The fraction Fr.A5 obtained after elution was subjected to semi-preparative HPLC and further purified by acetonitrile-water system to obtain the isopentenyl flavonoid compound.

4. The method for preparing the isopentenyl flavonoid compound according to claim 3, characterized in that: In the step (1), the gradient of dichloromethane-methanol is 100:1-1:1; the ethanol is industrial ethanol with a concentration of 70%, and reflux extraction is performed 3 times, each time for 2 hours.

5. The method for preparing the isopentenyl flavonoid compound according to claim 3, characterized in that: In the step (2), the gradient of ethanol-water is 20%-90%.

6. The method for preparing isopentenyl flavonoids according to claim 3, characterized in that: In the step (3), the acetonitrile-water ratios used for the three compounds are: broussoflavonol C, 38:62, v / v; daphnegiranol G, 25:75, v / v; daphnegiranol E, 27:78, v / v.

7. A pharmaceutical composition, characterized in that The invention comprises the isopentenyl flavonoid compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

8. Use of the isopentenyl flavonoid compound according to claim 1 or claim 2 in the preparation of anti-tumor drugs.

9. Use of the pharmaceutical composition according to claim 7 in the preparation of anti-tumor drugs.

10. The use according to claim 8 or claim 9, characterized in that: The tumor is liver cancer.

Citation Information

Patent Citations

  • Benzopyrone estrogen receptor (ER) modulator

    CN102558164A

  • Isopentenyl flavonoid compound in Daphne giraldii Nitsche. and application thereof

    CN111423403A

  • Diisopentenyl flavone compound as well as preparation method and application thereof

    CN111454241A

Cited By

  • Isopentenyl flavonoid compound as well as preparation method and application thereof

    CN120157644A